CD8A and melanoma: Treatment with BRAF inhibitors results in increased melanoma antigens and CD8 + T cells in tumors, which is associated with increased markers of T cell cytotoxicity, decreased immunosuppressive cytokines and vascular endothelial growth factor, and increased immunomodulatory molecules (PD-1, PD-L1 and TIM-3).